CINECA IRIS Institutional Research Information System

ROMEI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.958
EU - Europa 6.318
AS - Asia 5.587
SA - Sud America 783
AF - Africa 351
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 24.011
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.687
IT - Italia 2.306
SG - Singapore 1.720
CN - Cina 1.587
DE - Germania 1.215
HK - Hong Kong 891
SE - Svezia 870
BR - Brasile 649
VN - Vietnam 486
GB - Regno Unito 370
BG - Bulgaria 316
FR - Francia 224
RU - Federazione Russa 207
IN - India 198
CA - Canada 197
CI - Costa d'Avorio 190
FI - Finlandia 188
TR - Turchia 168
AT - Austria 151
UA - Ucraina 115
JP - Giappone 112
KR - Corea 102
NL - Olanda 88
SN - Senegal 63
BD - Bangladesh 60
IQ - Iraq 48
CH - Svizzera 46
AR - Argentina 42
PL - Polonia 40
MX - Messico 35
PK - Pakistan 35
EE - Estonia 32
ZA - Sudafrica 32
BE - Belgio 31
ES - Italia 25
ID - Indonesia 23
SA - Arabia Saudita 23
EC - Ecuador 22
MA - Marocco 21
CO - Colombia 20
UZ - Uzbekistan 20
CZ - Repubblica Ceca 14
GR - Grecia 14
VE - Venezuela 14
CL - Cile 11
IE - Irlanda 11
IR - Iran 11
JO - Giordania 11
TW - Taiwan 11
AZ - Azerbaigian 9
DZ - Algeria 9
IL - Israele 9
KE - Kenya 9
PH - Filippine 9
PS - Palestinian Territory 9
CR - Costa Rica 8
HU - Ungheria 8
LT - Lituania 8
PE - Perù 8
RO - Romania 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
PA - Panama 7
PY - Paraguay 7
UY - Uruguay 7
EG - Egitto 6
OM - Oman 6
PT - Portogallo 6
TN - Tunisia 6
BY - Bielorussia 5
JM - Giamaica 5
MY - Malesia 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
GT - Guatemala 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
AL - Albania 3
BH - Bahrain 3
EU - Europa 3
HN - Honduras 3
KG - Kirghizistan 3
KZ - Kazakistan 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BJ - Benin 2
BO - Bolivia 2
DK - Danimarca 2
GE - Georgia 2
LB - Libano 2
LK - Sri Lanka 2
AI - Anguilla 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BZ - Belize 1
CM - Camerun 1
CY - Cipro 1
Totale 23.989
Salva come PNG Salva come JPEG
Città #
Ashburn 1.187
Singapore 950
Dallas 869
Hong Kong 869
Fairfield 814
Woodbridge 784
Ann Arbor 689
Chandler 610
Santa Clara 583
San Jose 579
Houston 561
Seattle 341
Milan 336
Shanghai 327
Cambridge 318
Sofia 312
Beijing 308
Wilmington 271
New York 239
Abidjan 190
Los Angeles 174
Boardman 163
Serra 154
Princeton 143
Ho Chi Minh City 140
Ottawa 137
Vienna 137
Munich 124
Hefei 121
Jacksonville 121
Lauterbourg 116
Rome 116
Lawrence 115
Pisa 108
Medford 100
Seoul 98
Frankfurt am Main 97
Tokyo 97
Florence 96
Hanoi 83
Des Moines 82
London 79
Nanjing 70
Helsinki 68
Izmir 67
Council Bluffs 66
Dearborn 65
Dakar 63
Istanbul 60
Dong Ket 56
Buffalo 55
Boulder 54
Bremen 51
Naples 51
Redondo Beach 50
São Paulo 46
Redwood City 42
San Diego 41
Lancaster 38
Bern 37
Fuzhou 35
Orem 34
Washington 34
Bologna 33
Turku 32
Tianjin 31
Genoa 28
Brussels 27
Düsseldorf 27
Baghdad 26
Belo Horizonte 25
Columbus 25
Ogden 24
Grafing 23
Shenyang 23
Changsha 22
Mumbai 22
Phoenix 22
Redmond 22
Rio de Janeiro 22
Nanchang 21
Jüchen 20
Lucca 20
Atlanta 19
Warsaw 19
Kunming 17
Tashkent 17
Amsterdam 16
Brooklyn 16
Chicago 16
Johannesburg 16
Montreal 16
Palermo 16
Pune 16
Quanzhou 16
San Francisco 16
Toronto 16
Bengaluru 15
Hangzhou 15
Hebei 15
Totale 15.593
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.149
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 340
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 312
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 256
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 253
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 251
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 248
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 241
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 240
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 238
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 231
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 228
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 226
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 225
Targeted Therapy in Thyroid Cancer: State of the Art 223
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 222
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 221
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 219
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 219
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 216
Inherited variants in genes somatically mutated in thyroid cancer 216
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 213
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 212
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 208
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 207
RET point mutations in Thyroid Carcinoma 207
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 205
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 204
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 204
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 203
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 203
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 197
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 197
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 196
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 195
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 192
Genome-wide association study on differentiated thyroid cancer. 192
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 192
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 189
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 187
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 186
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 186
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 182
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk 181
The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans 180
Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system 180
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 178
Post-surgical follow-up of differentiated thyroid cancer. 177
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 176
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 176
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 176
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 175
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 175
Correction: Inherited variants in genes somatically mutated in thyroid cancer 175
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 175
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 174
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 171
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 170
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 170
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 165
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 165
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. 164
Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach 163
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 163
RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults 162
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 162
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 161
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 161
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma 161
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 160
Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. 159
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 159
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 157
null 157
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 157
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 156
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 154
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 154
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association 154
RET /PTC translocations and clinico-pathological features in human papillary thyroid carcinoma 153
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 153
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 153
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 152
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 152
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 151
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 150
Runs of homozygosity and inbreeding in thyroid cancer 149
Il ciglitazone induce inibizione della crescita in cellule di carcinoma midollare della tiroide (TT) verosimilmente dovuta ad un aumentata espressione di PPAR gamma 148
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 148
L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide 147
null 146
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 142
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 142
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 142
Medullary thyroid carcinoma in children 140
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 140
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 139
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 139
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 136
WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION 136
Totale 19.392
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.929
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.929
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021241 0 0 0 0 0 0 0 0 0 0 60 181
2021/20221.561 59 84 33 103 326 182 47 79 75 61 115 397
2022/20232.507 281 379 186 191 220 265 55 195 482 43 163 47
2023/20241.810 186 168 216 124 211 258 132 103 68 55 110 179
2024/20254.942 71 206 89 321 534 496 386 276 472 606 570 915
2025/20265.842 508 903 671 512 610 481 932 285 370 541 29 0
Totale 24.361